What is Global Hereditary Angioedema Treatment Market?
The Global Hereditary Angioedema Treatment Market is a specialized sector within the broader healthcare industry. Hereditary Angioedema (HAE) is a rare, genetic disorder characterized by recurrent episodes of severe swelling (angioedema). The swelling can occur in any part of the body but is most common in the face, hands, feet, and gastrointestinal tract. The global market for HAE treatment includes various therapeutic options such as C1 esterase inhibitors, selective bradykinin B2 receptor antagonists, and kallikrein inhibitors. The market also includes other treatments like conventional drugs and pipeline drugs that are currently under development. The growth of this market is driven by the increasing prevalence of HAE, advancements in medical technology, and the development of new treatment options. However, the high cost of treatment and lack of awareness about the disease are some of the challenges faced by this market.
C1 Estearse Inhibitors (Plasma Products, Recombinant Products), Selective Bradykinin B2 Receptor Antagonists (Firazyr), Kallikrein Inhibitors (Kalbitor, Takhzyro), Others (Conventional Drugs, Pipeline Drugs) in the Global Hereditary Angioedema Treatment Market:
The Global Hereditary Angioedema Treatment Market is segmented based on the type of treatment. C1 esterase inhibitors are proteins that help control inflammation and swelling in the body. They are available as plasma products and recombinant products. Selective bradykinin B2 receptor antagonists like Firazyr are used to treat acute attacks of HAE. Kallikrein inhibitors such as Kalbitor and Takhzyro are used to prevent HAE attacks. Other treatments include conventional drugs and pipeline drugs that are currently under development. Each of these treatments has its own advantages and disadvantages, and the choice of treatment depends on the patient's specific needs and medical history.
Hospital Pharmacies, Retail Pharmacies, Others (online pharmacies, mail pharmacies) in the Global Hereditary Angioedema Treatment Market:
The Global Hereditary Angioedema Treatment Market also varies based on the place of purchase. Hospital pharmacies are the primary point of purchase for most HAE treatments. This is because HAE is a serious condition that often requires hospitalization during acute attacks. Retail pharmacies also play a significant role in the market, especially for patients who are managing their condition at home. Other points of purchase include online pharmacies and mail pharmacies. These options offer convenience and often lower prices, making them an attractive choice for many patients. However, the availability of HAE treatments through these channels may be limited in some regions.
Global Hereditary Angioedema Treatment Market Outlook:
Based on our research, the global market for medical devices, which includes devices used in the treatment of HAE, is projected to reach a value of US$ 603 billion by the year 2023. This represents a significant increase from the current market value. The market is expected to grow at a compound annual growth rate (CAGR) of 5% over the next six years. This growth is driven by factors such as the increasing prevalence of chronic diseases, advancements in medical technology, and the growing demand for effective treatment options. However, the market also faces challenges such as regulatory hurdles and high costs of development and production.
| Report Metric | Details |
| Report Name | Hereditary Angioedema Treatment Market |
| Accounted market size in year | US$ 603 billion |
| CAGR | 5% |
| Base Year | year |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | CSL, Pharming Group, Shire plc (Takeda Pharmaceutical Company Limited), Ionis Pharmaceuticals, Attune Pharmaceuticals, BioCryst Pharmaceuticals, KalVista Pharmaceuticals |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
